Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Lei Deng, Lesli A. Kiedrowski, Elizabeth Ravera, Haiying Cheng, Balazs Halmos

Research output: Contribution to journal › Letter › peer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition'. Together they form a unique fingerprint.